On Tuesday, Nu Skin Enterprises, Inc. (NYSE:NUS)’s shares declined -0.87% to $42.18.
Kendall Law Group, led by former federal judge Joe Kendall, is investigating certain officers and directors of Nu Skin Enterprises, Inc. (NUS) on behalf of shareholders to determine whether Nu Skin officials breached their fiduciary duties to shareholders.
Nu Skin develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex brands worldwide. If you presently own shares of Nu Skin and want to know more about your rights, you are encouraged to contact Jamie McKey at the Kendall Law Group at 877-744-3728 or by email at [email protected] to learn more about your legal rights as a shareholder. .
Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex brands worldwide. The company offers skin-care systems and treatment products, such as ageLOC Spa systems, ageLOC Tru Face Essence Ultra anti-aging skin care serum, and ageLOC Transformation anti-aging skin care system, in addition to other cosmetic, personal care, and hair care products. It also provides LifePak; ageLOC R2 nutritional supplements; and ageLOC TR90 weight administration and body shaping systems.
Radius Health Inc (NASDAQ:RDUS)’s shares gained 8.93% to $79.90.
Radius Health, Inc. (RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis in addition to other serious endocrine-mediated diseases, counting hormone responsive breast cancer, declared recently that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting, October 9-12, 2015, at the Washington State Convention Center in Seattle, Washington, USA.
The company will be presenting a responder analysis of the effects of abaloparatide and teriparatide on bone mineral density in postmenopausal women with osteoporosis, the effects of abaloparatide on major osteoporotic fracture incidence in addition to pharmacokinetic data from the transdermal patch optimization program. Abstracts summarizing the abaloparatide data are published on the ASBMR website and are accessible to conference registrants and ASBMR members at: http://www.asbmr.org/ASBMR-abstracts.
Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has accomplished Phase II clinical trial, which is used to enhance bone mineral density.
At the end of Tuesday’s trade, Green Plains Inc (NASDAQ:GPRE)‘s shares surged 2.33% to $27.23.
Green Plains Partners declared the closing of its initial public offering of 11,500,000 common units representing limited partner interests at $15.00 per common unit. The number of common units issued at closing comprised of 1,500,000 common units that were issued following the full exercise of the underwriters’ option to purchase additional common units. The common units began trading on the NASDAQ Global Market on June 26, 2015 under the ticker symbol “GPP”. Net proceeds from the offering, after deducting underwriting discounts, structuring fees and estimated offering expenses, were about $157.9 million.
Following the closing of the offering, the public owns common units representing a 35.5% limited partner interest in Green Plains Partners. Green Plains Inc. (the “Parent”) (GPRE), together with certain of its wholly-owned auxiliaries, owns the remaining outstanding common units and subordinated units, collectively representing a 62.5% limited partner interest in Green Plains Partners, in addition to Green Plains Partners’ 2.0% general partner interest and Incentive Distribution Rights.
Green Plains Inc. produces, markets, and distributes ethanol in the United States. The company operates through four segments: Ethanol Production, Corn Oil Production, Agribusiness, and Marketing and Distribution. It produces ethanol and co-products, such as wet, modified wet, or dried distillers grains, in addition to extracts non-edible corn oil that is used as feedstock for biodiesel, livestock feed additives, rubber substitutes, rust preventatives, inks, textiles, soaps, and insecticides.
Packaging Corp Of America (NYSE:PKG), ended its Tuesday’s trading session with 0.89% gain, and closed at $64.46.
Packaging Corporation of America (PKG) will hold a conference call on Wednesday, July 22, 2015 at 10:00 a.m. (Eastern Time) to talk about second quarter 2015 results. The second quarter earnings results will be released after the market closes on Tuesday, July 21, 2015.
Packaging Corporation of America manufactures and sells containerboard and corrugated packaging products in the United States, Europe, Mexico, and Canada. The company’s Packaging segment offers various corrugated packaging products, such as conventional shipping containers used to protect and transport manufactured goods; multi-color boxes and displays that assist to merchandise the packaged product in retail locations; and honeycomb protective packaging.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
